RNAC Cartesian Therapeutics, Inc.

company

SEC Filings & Insider Trading Activity 2026

Business Overview

• • Core business: Late clinical-stage biopharma pioneering outpatient mRNA-engineered autologous cell therapies for autoimmune diseases targeting B-cell maturation antigen (BCMA)
• • New emphasis: Expansion of Descartes-08 into myositis (dermatomyositis, antisynthetase syndrome) with FDA IND accepted December 2025, Phase 2 trial to start H1 2026
• • Strategic shift: Prioritization of Descartes-08 development after pausing Descartes-08 in SLE and halting Descartes-15 for multiple myeloma to focus on MG and myositis
• • Quantitative highlight: Over 100 patients treated with Descartes-08 outpatient through Phase 1/2 trials; Phase 3 AURORA trial launched May 2025 targeting 100 MG patients
• • Noteworthy: FDA granted Orphan Drug, RMAT, and Rare Pediatric Disease Designations for Descartes-08; first mRNA CAR-T with no CRS, neurotoxicity, or genomic integration risks reported

Risk Factors

• • FDA investigation of T-cell malignancy risk for CAR-T therapies including Descartes-08, with potential for boxed warnings or REMS requirements in 2024-2025
• • Geopolitical conflict risks delaying patient enrollment in clinical trials, impacting multinational trial sites and timelines
• • Supply chain vulnerability due to reliance on third-party manufacturers for patient-specific mRNA CAR-T product candidates
• • Competition from DNA-based CAR-T therapies with established FDA approvals and safety track records
• • Cash burn risks from clinical trial delays and increased development costs, with potential premature trial termination impacting financial condition

Management Discussion & Analysis

• • Revenue $2.8M in 2025 vs $38.9M in 2024, collaboration and license revenue down $37.9M primarily from Sobi License milestone
• • Operating expenses $146.2M in 2025 vs $82.8M in 2024, R&D up 29% to $58.0M, G&A slightly up 4% to $31.5M
• • Operating loss $(143.4)M in 2025 vs $(43.9)M in 2024; net loss $(130.3)M vs $(77.4)M, loss increased 68%
• • Best segment: Grant revenue $2.4M in 2025, up $1.8M; worst segment: collaboration/license revenue down 99% to $0.4M
• • Cash $126.9M at year-end; $60.25M raised via Series A Preferred in 2023 Private Placement; no product sales yet
• • Management expects continued significant R&D, operating losses, and reliance on equity/debt financings; revenue from product sales not expected for several years

What are the latest RNAC SEC filings in 2026?

Cartesian Therapeutics, Inc. (RNAC) has filed a 10-K annual report on March 9, 2026, a 10-Q quarterly report on April 30, 2026, an 8-K current report on August 6, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.

When did RNAC file its most recent 10-K annual report?

Cartesian Therapeutics, Inc. (RNAC) filed its most recent 10-K annual report on March 9, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.

How do I view RNAC 10-Q quarterly reports?

Cartesian Therapeutics, Inc. (RNAC)'s most recent 10-Q quarterly report was filed on April 30, 2026. SignalX displays every RNAC 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.

What 8-K current reports has RNAC filed recently?

Cartesian Therapeutics, Inc. (RNAC)'s most recent 8-K was filed on August 6, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.

Where can I find RNAC insider trading activity (Form 4)?

SignalX aggregates every RNAC Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.

How often does RNAC file with the SEC?

Cartesian Therapeutics, Inc. (RNAC) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new RNAC filing with AI-powered analysis.

What is the difference between 10-K, 10-Q, and 8-K SEC filings?

A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs, such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for Cartesian Therapeutics, Inc. (RNAC).

What is RNAC's SEC CIK number?

Cartesian Therapeutics, Inc. (RNAC)'s SEC CIK (Central Index Key) number is 1453687. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1453687 to look up all RNAC filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.

Where can I find RNAC return on equity (ROE) and financial data?

SignalX extracts XBRL financial data from Cartesian Therapeutics, Inc. (RNAC) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.